이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Becton Dickinson 미래 성장

Future 기준 확인 3/6

Becton Dickinson (는) 각각 연간 18% 및 5.4% 수익과 수익이 증가할 것으로 예상됩니다. EPS는 연간 17.5% 만큼 성장할 것으로 예상됩니다. 자기자본이익률은 3년 후 15.5% 로 예상됩니다.

주요 정보

18.0%

수익 성장률

17.5%

EPS 성장률

Medical Equipment 수익 성장	18.1%
매출 성장률	5.4%
향후 자기자본 수익률	15.5%
애널리스트 커버리지	Good
마지막 업데이트	14 Jun 2024

최근 미래 성장 업데이트

Recent updates

수익 및 매출 성장 예측

BUL:BOX - 애널리스트의 미래 추정치 및 과거 재무 데이터 (USD Millions )
날짜	수익	수익	잉여 현금 흐름	작전 현금	평균 애널리스트 수
9/30/2026	22,642	2,808	4,108	5,079	11
9/30/2025	21,419	2,479	4,150	4,694	15
9/30/2024	20,249	2,094	2,973	3,834	16
3/31/2024	19,716	1,364	3,025	3,760	N/A
12/31/2023	19,492	1,265	2,649	3,431	N/A
9/30/2023	19,372	1,470	2,115	2,989	N/A
6/30/2023	19,046	1,582	1,878	2,773	N/A
3/31/2023	18,809	1,556	1,009	1,966	N/A
12/31/2022	18,738	1,486	1,361	2,359	N/A
9/30/2022	18,870	1,545	1,661	2,634	N/A
6/30/2022	18,958	1,412	1,465	2,575	N/A
3/31/2022	18,924	1,430	2,041	3,141	N/A
12/31/2021	18,534	1,079	2,620	3,751	N/A
9/30/2021	19,131	1,514	3,453	4,647	N/A
6/30/2021	19,066	1,486	4,222	5,177	N/A
3/31/2021	18,313	1,379	4,150	5,064	N/A
12/31/2020	18,207	1,507	3,476	4,359	N/A
9/30/2020	16,074	245	2,728	3,497	N/A
6/30/2020	16,917	786	2,474	3,429	N/A
3/31/2020	17,414	923	2,509	3,499	N/A
12/31/2019	17,355	760	2,835	3,798	N/A
9/30/2019	17,290	1,081	2,373	3,330	N/A
6/30/2019	17,108	784	2,359	3,265	N/A
3/31/2019	17,036	926	2,009	2,875	N/A
12/31/2018	17,063	894	1,906	2,790	N/A
9/30/2018	15,983	159	1,970	2,865	N/A
6/30/2018	14,747	621	1,837	2,685	N/A
3/31/2018	13,503	-99	1,681	2,527	N/A
12/31/2017	12,251	294	N/A	2,555	N/A
9/30/2017	12,093	1,030	N/A	2,550	N/A
6/30/2017	12,158	759	N/A	2,129	N/A
3/31/2017	12,321	1,314	N/A	2,579	N/A
12/31/2016	12,419	1,309	N/A	2,411	N/A
9/30/2016	12,483	976	N/A	2,559	N/A
6/30/2016	12,312	1,139	N/A	2,532	N/A
3/31/2016	12,234	810	N/A	2,236	N/A
12/31/2015	11,217	688	N/A	1,907	N/A
9/30/2015	10,282	695	N/A	1,730	N/A
6/30/2015	9,410	815	N/A	1,591	N/A
3/31/2015	8,448	1,079	N/A	1,492	N/A
12/31/2014	8,468	1,150	N/A	1,677	N/A
9/30/2014	8,446	1,185	N/A	1,746	N/A
6/30/2014	8,345	974	N/A	1,876	N/A
3/31/2014	8,239	941	N/A	1,830	N/A
12/31/2013	8,169	930	N/A	1,626	N/A
9/30/2013	8,054	929	N/A	1,505	N/A

애널리스트 미래 성장 예측

수입 대 저축률: BOX 의 연간 예상 수익 증가율( 18% )이 saving rate( 3% 보다 높습니다. ).

수익 vs 시장: BOX 의 연간 수익( 18% ) BG 시장( 12.3% 보다 빠르게 성장할 것으로 예상됩니다. 12.3% 연간).

고성장 수익: BOX 의 수입은 증가할 것으로 예상되지만 상당히 증가하지는 않을 것입니다.

수익 대 시장: BOX 의 수익(연간 5.4% ) BG 시장( 5% 보다 빠르게 성장할 것으로 예상됩니다. 5% 연간).

고성장 수익: BOX 의 수익(연간 5.4% )은 연간 20% 보다 느리게 증가할 것으로 예상됩니다.

주당 순이익 성장 예측

미래 자기자본 수익률

미래 ROE: BOX 의 자본 수익률은 3년 내에 최저 수준이 될 것으로 예상됩니다( 15.5 %).

Becton Dickinson 미래 성장

Future 기준 확인 3/6

주요 정보

최근 미래 성장 업데이트

Becton, Dickinson and Company Revises Earnings Guidance for the Fiscal Year 2024

Becton, Dickinson and Company Raises Earnings Guidance for the Fiscal Year of 2024

Becton, Dickinson and Company Provides Earnings Guidance for the Fiscal Year 2024

Becton, Dickinson and Company Raises Earnings Guidance for the Fiscal Year 2023

Becton, Dickinson and Company Raises Earnings Guidance for the Fiscal Year 2023

Becton, Dickinson and Company Provides Earnings Guidance for the Year 2023

Recent updates

BD (Becton, Dickinson and Company) Announces the Commercial Launch of a New Single-Cell Research Tool

Becton, Dickinson and Company (NYSE:BDX) entered into an agreement to acquire Critical Care Product Group of Edwards Lifesciences Corporation (NYSE : EW) for $4.2 billion.

Becton, Dickinson and Company Revises Earnings Guidance for the Fiscal Year 2024

Second quarter 2024 earnings released: EPS: US$1.86 (vs US$1.54 in 2Q 2023)

Becton, Dickinson and Company Declares Quarterly Dividend, Payable on June 28, 2024

Becton, Dickinson and Company (NYSE:BDX) acquired FlowJo LLC.

Becton, Dickinson and Company to Report Q2, 2024 Results on May 02, 2024

Becton, Dickinson and Company Initiates International Study to Expand Treatment Options for Patients with Peripheral Arterial Disease

Dave Hickey Retires as Executive Vice President and President of the Life Sciences Segment for BD, Effective from July 1, 2024

First quarter 2024 earnings released: EPS: US$0.97 (vs US$1.71 in 1Q 2023)

Becton, Dickinson and Company Raises Earnings Guidance for the Fiscal Year of 2024

Becton, Dickinson and Company Declares Quarterly Dividend, Payable on March 29, 2024

Becton, Dickinson and Company to Report Q1, 2024 Results on Feb 01, 2024

Becton, Dickinson and Company, Annual General Meeting, Jan 23, 2024

BD Receives FDA 510(K) Clearance for Potentially Transformative Fingertip Blood Collection Device

BD Launches Advanced Vascular Access Ultrasound System Designed to Improve Clinician Efficiency

Becton, Dickinson and Company Announces Executive Changes

New minor risk - Earnings quality

Full year 2023 earnings released: EPS: US$5.14 (vs US$5.42 in FY 2022)

Becton, Dickinson and Company Increases Quarterly Dividend, Payable on December 29, 2023

Becton, Dickinson and Company Increases Quarterly Dividend, Payable on December 29, 2023

Becton, Dickinson and Company Provides Earnings Guidance for the Fiscal Year 2024

Now 22% undervalued after recent price drop

Becton, Dickinson and Company Announces Launch of Next-Generation Needle-Free Blood Draw Technology

BD Names Greg Rodetis as Senior Vice President of Investor Relations

Becton, Dickinson and Company to Report Q4, 2023 Results on Nov 09, 2023

Now 21% undervalued

New minor risk - Earnings quality

Becton, Dickinson and Company Raises Earnings Guidance for the Fiscal Year 2023

Third quarter 2023 earnings released: EPS: US$1.37 (vs US$1.29 in 3Q 2022)

Becton, Dickinson and Company Elects Joanne Waldstreicher to the Board and as Member of the Corporate Governance and Nominating Committee and the Quality and Regulatory Committee of the Board

Becton, Dickinson and Company Receives FDA 510(k) Clearance for Updated BD Alaris™? Infusion System

Becton, Dickinson and Company to Report Q3, 2023 Results on Aug 03, 2023

STERIS Corporation agreed to acquire Surgical Instrumentation platform from Becton, Dickinson and Company for $540 million.

Second quarter 2023 earnings released

Becton, Dickinson and Company Raises Earnings Guidance for the Fiscal Year 2023

BD Receives FDA Emergency Use Authorization for COVID-19, Influenza A/B, RSV Combination Test

Becton, Dickinson and Company Introduces High-Throughput Single-Cell Multiomics Platform to Expand Scope of Scientific Discovery

First quarter 2023 earnings released: EPS: US$1.71 (vs US$2.30 in 1Q 2022)

Becton, Dickinson and Company Provides Earnings Guidance for the Year 2023

BD (Becton, Dickinson and Company) Declares Quarterly Dividend, Payable on March 31, 2023

Becton, Dickinson and Company Introduces Fully Automated Robotic Track System for Microbiology Labs

Becton, Dickinson and Company and CerTest Biotec Announce Emergency Use Authorization from U.S. Food and Drug Administration for Molecular Polymerase Chain Reaction Assay for Mpox Virus Detection

Becton, Dickinson and Company Announces Executive Changes

Becton, Dickinson and Company to Report Q1, 2023 Results on Feb 02, 2023

Becton, Dickinson and Company, Annual General Meeting, Jan 24, 2023

Now 20% undervalued

Full year 2022 earnings released: EPS: US$5.42 (vs US$5.23 in FY 2021)

수익 및 매출 성장 예측

애널리스트 미래 성장 예측

주당 순이익 성장 예측

미래 자기자본 수익률

성장 기업 발견